Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|June 24, 2019
FDA Approves Amgen and Allergan's Biosimilar to Herceptin
Author(s)Pharmaceutical Technology Editors
The biosimilar, Kanjinti, is approved for all indications of Herceptin, which includes treating breast, gastric, and gastroesophogeal cancers.
Advertisement
Amgen and Allergan announced on June 13, 2019 that they have received approval from FDA for Kanjinti (trastuzumab-anns), a biosimilar referencing Roche’s Herceptin (trastuzumab), for all approved indications of Herceptin in treating HER2-overexpressing adjuvant and metastatic breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
Herceptin is one of Roche’s leading drug products with CHF 6.98 billion (US$7.16 billion) in 2018 sales. Amgen and Allergan’s biosimilar, Kanjinti, was proven to be highly similar to, and to have no clinically meaningful differences from, Herceptin. The similarity was based on extensive comparative analytical, pharmacokinetic, and clinical data.
"The FDA approval of Kanjinti is an important milestone for our biosimilars portfolio, providing an additional treatment option for patients across three types of cancer," said David M. Reese, MD, executive vice president of research and development at Amgen, in a company press release.
"Kanjinti is the second of four biosimilars from Amgen and Allergan's collaboration to be approved by [FDA]," said David Nicholson, chief research and development officer at Allergan, in the release. "We are proud of the progress being made as we continuously strive to develop and deliver high-quality cancer therapies in collaboration with Amgen."
Amgen has a total of 10 biosimilars in its portfolio, three of which have been approved in the United States and three that are approved in the European Union.
Source:
Advertisement
Related to this article
The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
Advertisement
Advertisement